ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailMenu BurgerPositive ArrowIcon PrintIcon SearchSite TitleTitle ChevronIcon Twitter
Health Technology

Takeda Pharmaceutical Co., Ltd.

  • 3,543.00 JPY
  • +17.00
  • +0.48%
  • Japan
    Aug 21, 2019
  • Ticker
    TKS(4502)
  • Prev. close
    3,526
  • Market cap (JPY)
    5,558.23B
  • Market cap (USD)
    52,199.77M
  • Shares
    1,576.35M

Business Summary

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

Financial Highlights

Mar 2019 JPYUSD
Revenue2,097.22B18,911.85M
Gross Profit1,242.84B11,207.41M
Operating income181,857M1,639.90M
Income before tax94,896M855.73M
Net income109,126M984.05M
EBITDA454,303M4,096.70M
Diluted EPS112.861.01
Dividends Per Share1801.62
Total Assets13,872.32B125,331.55M
Total liabilities8,708.73B78,680.35M
Total equity5,159.58B46,615.00M
Operating cash flow302,609M2,728.79M
Currency in JPYCurrency in USD

Historical Data

 Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019
Revenue 1,777.82B 1,807.37B 1,732.05B 1,770.53B 2,097.22B
Gross Profit 1,134.39B 1,161.84B 1,017.65B 1,148.86B 1,242.84B
Operating income 195,804M 175,770M 86,972M 195,320M 181,857M
Income before tax -145,437M 120,539M 143,346M 217,205M 94,896M
Net income -145,775M 80,166M 114,940M 186,886M 109,126M
EBITDA 387,391M 353,275M 258,398M 377,447M 454,303M
Diluted EPS -185.37 101.71 146.25 237.55 112.86
Dividends Per Share 180 180 180 180 180
Total Assets 4,296.19B 3,824.08B 4,346.79B 4,106.46B 13,872.32B
Total liabilities 2,090.01B 1,812.88B 2,397.82B 2,089.05B 8,708.73B
Total equity 2,137.04B 1,948.69B 1,894.26B 1,997.42B 5,159.58B
Operating cash flow 183,441M 26,552M 260,067M 379,600M 302,609M
 Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019
Revenue 16,183.14M 15,050.91M 15,994.93M 15,974.84M 18,911.85M
Gross Profit 10,326.11M 9,675.22M 9,397.74M 10,365.80M 11,207.41M
Operating income 1,782.36M 1,463.72M 803.15M 1,762.30M 1,639.90M
Income before tax -1,323.88M 1,003.78M 1,323.75M 1,959.76M 855.73M
Net income -1,326.95M 667.58M 1,061.43M 1,686.20M 984.05M
EBITDA 3,526.33M 2,941.89M 2,386.22M 3,405.56M 4,096.70M
Diluted EPS -1.68 0.84 1.35 2.14 1.01
Dividends Per Share 1.63 1.49 1.66 1.62 1.62
Total Assets 35,823.98M 34,023.62M 39,009.18M 38,612.71M 125,331.55M
Total liabilities 17,427.69M 16,129.56M 21,518.70M 19,643.19M 78,680.35M
Total equity 17,819.86M 17,337.88M 16,999.56M 18,781.60M 46,615.00M
Operating cash flow 1,669.82M 221.11M 2,401.63M 3,424.99M 2,728.79M

Valuation Measures

Mar 2019
PER39.83
ROA1.21%
ROE3.04%
Operating margin8.67%
Profit margin5.20%

Key executives

  • President, CEO & Representative Director: Christophe Weber
  • Chief Financial Officer: Costa Saroukos
  • Director, Chief Medical & Scientific Officer: Andrew S. Plump
  • Executive Officer & Global General Counsel: Yoshihiro Nakagawa
  • Global Human Resources Officer & Executive Officer: David Osborne

Shareholders

  • Sumitomo Mitsui Trust Asset Management Co., Ltd. (3.3%)
  • BlackRock Fund Advisors (3.1%)
  • Asset Management One Co., Ltd. (2.7%)
  • Causeway Capital Management LLC (2.6%)
  • Nippon Life Insurance Co. (2.2%)
  • The Vanguard Group, Inc. (1.9%)
  • Capital Research & Management Co. (World Investors) (1.7%)
  • Nomura Asset Management Co., Ltd. (1.6%)
  • Nikko Asset Management Co., Ltd. (1.5%)
  • State Street Global Advisors Ltd. (1.5%)

Contact Details

Related Companies

  • Takeda Re Insurance AG
  • Takeda Pharmaceutical Co. Ltd. /Tachosil Business/
  • Plasmapunkt Favoriten GmbH
  • Takeda Malaysia Sdn. Bhd.
  • Takeda Pharmaceutical Co. Ltd. /Latam Bus/
  • Takeda Oranienburg Real Estate GmbH & Co. KG
  • Takeda Consumer Healthcare Co. Ltd.
  • Takeda Pharmaceutical Director Incentive Plan
  • Takeda Pharmaceutical Employee Incentive Plan
  • Oy Leiras Takeda Pharmaceuticals AB
  • Takeda Architectural Design Consulting (Shanghai) Co. Ltd.
  • Takeda Pharma AB
  • Takeda Development Center Americas, Inc.
  • Takeda Ukraine LLC
  • Takeda Pharmaceuticals Taiwan Ltd.
  • Takeda SRL
  • Takeda Hellas SA
  • Takeda Christiaens SCA/CVA
  • Takeda Belgium SCA/CVA
  • Takeda Vaccines Pte Ltd.
  • Takeda Pharmaceuticals (Asia Pacific) Pte Ltd.
  • Takeda Development Center Asia Pte Ltd.
  • Takeda Pharma Sp zoo
  • Takeda Mexico SA de CV
  • Takeda Kazakhstan LLP
  • Takeda Pharmaceuticals Korea Co., Ltd.
  • Takeda Farmaceutica Espana SA
  • Takeda Pharma Ltda.
  • Takeda Distribuidora Ltda.
  • Takeda Vaccines, Inc.

Competitors

  • Dr. Reddy's Laboratories Ltd.
  • Sanofi
  • AstraZeneca PLC
  • Green Cross Corporation
  • Ipsen SA
  • MorphoSys AG
  • Amgen Inc.
  • Eli Lilly and Company
  • Hanmi Pharmaceutical Co., Ltd.
  • Daewoong Co., Ltd.
  • Faes Farma, S.A.
  • Grifols, S.A. Class A
  • Hypera S.A.
  • Celgene Corporation
  • JSC Kyivmedpreparat
  • Sangamo Therapeutics, Inc.
  • Endo International Plc
  • Assembly Biosciences, Inc.
  • Hutchison China MediTech Limited
  • Nektar Therapeutics
  • Gossamer Bio, Inc.
  • Moderna, Inc.
  • Genmab A/S
  • Hanall Biopharma Co., Ltd.
  • RedHill Biopharma Ltd.
  • Ironwood Pharmaceuticals, Inc. Class A
  • Morphic Holding, Inc.
  • Spectrum Pharmaceuticals, Inc.
  • Galapagos NV
  • Chimerix, Inc.
Last Updated on 21 Aug, 2019

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Get Unlimited access

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends June 30th

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media